Long-term effect of nintedanib treatment in 11 countries of Europe and Asia
Bildiriler > Özet Bildiri
Yazarlar: M Koziar Vasakova, M Sterclova, N Mogulkoc Bishop, K Lewandowska, V Müller, M Kramer, M Hajkova, D Jovanovic, M Studnicka, J Tekavec-Trkanjec, A Penev, P Ovesna, J Gregor
12.01 - Idiopathic interstitial pneumonias, , , Uluslararası, Özet Bildiri, ss 3391-3391
DOI: 10.1183/13993003.congress-2022.3391
Özet
Aims: Nintedanib (NIN), which was introduced to IPF treatment in 2014, is known to slow down IPF progression; however, data on long term effect of NIN on overall survival (OS) in large IPF cohorts are scarce. We aimed to investigate nintedanib therapy outcome in a large multicentric real-world cohort of IPF patients with various initial stages of the disease. Methods: Our study included 869 IPF patients treated with NIN and 691 controls with no antifibrotic treatment (NAF) enrolled for the EMPIRE registry in years 2015–2020. We compared OS in both groups with further stratification to mild, moderate, and advanced disease at baseline (FVC predicted >80%, 50–80%, and <50%). The baseline was defined either as NIN therapy initiation (NIN group) or enrolment (NAF group). Results: The NIN patients had higher BMI, more frequently UIP pattern on HRCT, longer duration of symptoms, and lower FVC, were significantly younger and more frequently never-smokers. OS was higher in NIN vs NAF (median OS 66.1 vs. 34.7 months, adjusted HR 0.40). A consistent favourable NIN outcome was observed in all three groups with different FVC predicted at baseline: median OS not reached vs 62.2 mo in the FVC >80%, 62.6 vs 23.5 mo in the FVC 50–80%, and 37.2 vs 12.0 mo in the FVC <50% group. Conclusion: Nintedanib treatment in IPF patients can substantially prolong life expectancy in real world. This effect was evident in all cohort of patients despite the NAF group having had better initial characteristics. We are aware of the limitations of our real-world study compared to randomized clinical trials; on the other hand, the number of the patients enrolled and the length of follow-up can support the persuasiveness of our conclusions.